Member Login

Lost your password?

Not a member yet? Sign Up!

The FDA is Our Ally

October 31, 2013
By

 

  News recently broke of our plan to approach the Food and Drug Administration (FDA) in early 2014 and begin human trials in early 2015. This is an exciting and incredibly promising development for our research and, even more so, for the cancer community. With each step we take, no matter how small, we inch closer to reaching human trials. The process of finalizing and legitimizing cancer research can be a lengthy one. Conducting laboratory tests, getting positive, reassuring results and drastically advancing our progress in finding “a better way” is simply not enough. The Kanzius Cancer Research Foundation needs FDA approval to make John Kanzius’ dream of finding a side effect free, noninvasive cancer treatment a reality.

 

Although time-consuming, the meticulous process towards FDA approval is necessary and provides us with the next stepping stone to reach human trials. I visited the FDA website (fda.gov) to dig deeper into what role the organization has in the Kanzius research timeline and was pleased to find their emphasis on medical innovation. The “FDA is responsible for protecting the public health by assuring the safety, efficacy and security of humans.” In addition, they are also in charge of “advancing the public health by helping to speed innovations that make medicines more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medicines and foods to maintain and improve their health.”

 

While I understand people’s frustration with this process, I view the FDA as our near and dear ally— a fellow soldier in the war on cancer and the strongest defender of cancer patients’ rights. There are those that have contrary opinions and believe that the FDA will hinder the advancement of our research. However, rumors and conspiracy theories such as these only muddy our passion, vision and effectiveness in finishing our job and starting to save lives. To date, the FDA has had nothing but words of encouragement and praise for our research and the promise it offers cancer patients. The proof is in the data; the outcomes will determine our destiny.

 

Dr. Steven Curley, lead researcher for the Kanzius Project in Houston, is particularly invested in seeing the Kanzius Noninvasive Radiowave Cancer Treatment gain FDA approval and reach human trials. A long-time friend of the late John Kanzius, Dr. Curley made a promise to John that he would see his treatment through to human trials—a promise that he fully intends to keep.

 

While Dr. Curley and our research team have conducted tests which have shown that the GenV Kanzius Device and the treatment have not caused any negative or toxic side effects in large, nonhuman laboratory subjects, the FDA will be responsible for ensuring that both the device and the treatment are also harmless and totally safe for humans.

 

The expeditious and hard work of our donors, volunteers and advocates has not gone unnoticed. Your support and dedication to the Kanzius Cancer Research Foundation has led us to this crucial point. Your actions proclaim its urgency. The results of our research have proven the treatment’s effectiveness and it is now time to expedite the process through the FDA. The Kanzius Cancer Research Foundation’s mission has always been to fund the research of this treatment through to human trials and to bring John Kanzius’ dream to fruition—meeting with the FDA brings us closer to reaching that goal.

 

Throughout the approval process, we must realize that the Kanzius Cancer Research Foundation and the FDA are on the same page and fighting the same fight: allowing innovation in the field of cancer treatment while ensuring the patients’ rights are preserved and their safety is protected. We, as a cancer community, have done our part. Now comes the difficult task of remaining patient as the FDA does theirs.

 

  MARK A. NEIDIG SR. is executive director of the Kanzius Cancer Research Foundation (MNeidig@Kanzius.org).

WordPress Plugin Share Bookmark Email